Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer

Abstract

The invention relates to application of an ALDH3A1 / IL-17 axis in preparation of a medicine for treating refractory ulcer. According to the invention, proteomics is combined with biological information analysis, and experimental verification is combined for use, so the protein expression of ALDH3A1 in a wound surface of a db / db diabetic mouse is reduced; and by overexpressing ALDH3A1 expression in HaCaT cells, proliferation of the cells is increased, inflammatory infiltration is relieved, and an IL-17 pathway is remarkably inhibited. It is prompted in the invention that ALDH3A1 can improve chronic inflammation, promote cell proliferation and heal wounds by inhibiting downstream IL-17 signal channels, and the targeted ALDH3A1 / IL-17 axis can be used as a novel treatment method and is used for treating refractory ulcers, chronic inflammation after injury, infection and other types of wounds in the future.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of the ALDH3A1 / IL-17 axis in the preparation of refractory ulcer medicine. Background technique [0002] The skin is the organ that the human body has the most contact with the environment, and is directly exposed to the surrounding environment. It has functions such as sensory and immune protection, and is also vulnerable to injury and infection. Wound healing is impaired in diabetes, vascular disease, and elderly patients. Diabetic ulcers (DUs) are a serious complication of diabetes, which often occur on the feet of patients, so they are also called diabetic feet. The disability rate and recurrence rate are extremely high, and the incidence rate increases year by year along with the increase in the prevalence of diabetes. Clinical studies have shown that by controlling blood sugar levels and wound infection, DUs still take a long time to heal, and the woun...

AI Technical Summary

Problems solved by technology

[0006] At present, only platelet-derived growth factor (PDGF-BB) has been approved by the US FDA for wound healing, but because of its high price, patients are often unaffordable

Although other growth factor preparations (EGF, bFGF) have certain curative effects, there are problems such as easy degradation, inconvenient drug storage, and easy to cause hypertrophic scars, which limit their popularization and application; there are even reports that some new excipients have certain carcinogenic risks

Images